Both @entity1378 and @entity1375 have been noted to occur in some @entity1 treated with @entity2643 for @entity943 . To determine the frequency of the development of @entity1374 in @entity1 receiving @entity2643 , 45 euthyroid @entity1 were prospectively evaluated. Serum samples were obtained for measurement of @entity1955 , @entity7287 , @entity1954 , and @entity1954 resin uptake prior to initiation of @entity2643 treatment and serially over a 12- to 27-month period during which @entity2643 was administered. The @entity1 were divided into four subgroups as follows: Group I (n = 22) had elevated @entity1955 levels, Group IIA (n = 13) had normal @entity1955 levels and normal thyrotropin levels, Group IIB (n = 7) had normal @entity1955 levels and elevated thyrotropin levels, and Group III (n = 3) had subnormal @entity1955 levels. Demographic factors (such as route of administration, cardiac diagnosis, sex of the @entity1 , or indication for @entity2643 therapy) and @entity2643 levels had no significant effect on the thyroid hormone parameters. However, Group I @entity1 were statistically older than the @entity1 in the other groups. Linear regression analysis revealed a negative correlation for @entity1955 levels and a positive correlation with thyrotropin levels with age for the whole group. The various groups were not statistically affected by duration of therapy, but a positive trend existed for increasing @entity1955 levels. Although virtually all @entity1 showed changes in their thyroid hormone levels, chemical @entity1378 (elevated @entity1955 and @entity1954 levels without symptoms) developed in only two @entity1 (4 percent), and clinical @entity1378 (elevated @entity1955 and @entity1954 levels with symptoms) developed in no @entity1 . Four @entity1 (9 percent) became biochemically and clinically @entity1375 . Thus, @entity2643 frequently influences thyroid hormonal parameters, but less commonly causes a change in actual thyroid function. However, @entity1378 and @entity1375 do occur in a significant number of @entity1 .

Effect of long-term XXXX therapy on thyroid hormone levels and thyroid function.

@entity1 :: ('9606', 'Species') :: ['patients', 'patient'] @entity1375 :: ('MESH:D007037', 'Disease') :: ['hypothyroidism', 'hypothyroid'] @entity2643 :: ('MESH:D000638', 'Chemical') :: ['amiodarone'] @entity1955 :: ('MESH:D013974', 'Chemical') :: ['thyroxine'] @entity1378 :: ('MESH:D006980', 'Disease') :: ['hyperthyroidism'] @entity7287 :: ('MESH:D013972', 'Chemical') :: ['thyrotropin'] @entity943 :: ('MESH:D001145', 'Disease') :: ['cardiac arrhythmias'] @entity1954 :: ('MESH:D014284', 'Chemical') :: ['triiodothyronine'] @entity1374 :: ('MESH:D013959', 'Disease') :: ['thyroidal abnormalities']
@entity2643 :: (MESH:D000638,Chemical) :: ['amiodarone']
